Virus News and Research

Latest Virus News and Research

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Response Biomedical strengthens patent protection for RAMP technology

Response Biomedical Corporation today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.

20 Dec 2010

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

20 Dec 2010

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

Global Fund approves 79 grants with two-year commitment of $1.7B

The Global Fund to Fight AIDS, Tuberculosis and Malaria Board of Directors on Wednesday approved 79 grants with a two-year commitment of "$1.7 billion dollars for projects against the diseases, amid warnings that some hard-hit African countries were being left out," Agence France-Presse reports. The commitment, according to Ethiopian Health Minister Tedros Adhanom Ghebreyesus, who chairs the Global Fund's board, "shows that even in hard economic times, we can continue to expand the fight against the three diseases" (12/15).

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

U.S., South Africa sign PEPFAR partnership agreement

Secretary of State Hillary Rodham Clinton and South African International Relations and Cooperation Minister Maite Nkoana-Mashabane on Tuesday signed a "partnership agreement that will guide efforts on fighting HIV/AIDS in the African nation," Bloomberg BusinessWeek reports (Wessels, 12/15).

17 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

HIV patient cured!

German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, “Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It’s as good an outcome as one could hope for.”

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

$Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea$

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).

16 Dec 2010

New finding sheds light on how HIV eludes treatment by mutating

The virus that causes AIDS is chameleon-like in its replication. As HIV copies itself in humans, it constantly mutates into forms that can evade even the best cocktail of current therapies. Understanding exactly how HIV cells change as they reproduce is key to developing better tests and treatments for patients.

16 Dec 2010

Novel adenovirus-based gene therapy for renal cell carcinoma

Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.

16 Dec 2010

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Carrageenan, is a polymer derived from red seaweed which helps to create a protective physical barrier in the nasal cavity and has proven to be an effective antiviral in the treatment of the common cold.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

Virus News and Research

Latest Virus News and Research

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Exciting progress made in MS research during 2010

Response Biomedical strengthens patent protection for RAMP technology

InterMune's MAA for Esbriet receives positive CHMP opinion

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Prions responsible for BSE can survive in new host environment

Global Fund approves 79 grants with two-year commitment of $1.7B

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

U.S., South Africa sign PEPFAR partnership agreement

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

HIV patient cured!

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

New finding sheds light on how HIV eludes treatment by mutating

Novel adenovirus-based gene therapy for renal cell carcinoma

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in